Ritu Baral
Stock Analyst at TD Cowen
(2.98)
# 1,335
Out of 5,157 analysts
45
Total ratings
40%
Success rate
3.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $35 → $37 | $22.54 | +64.15% | 3 | Feb 26, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $202 → $306 | $261.08 | +17.21% | 1 | Jan 9, 2026 | |
| VTVT vTv Therapeutics | Initiates: Buy | $67 | $35.02 | +91.32% | 1 | Jan 5, 2026 | |
| INSM Insmed | Maintains: Buy | $269 → $241 | $143.85 | +67.54% | 7 | Dec 18, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $97 → $133 | $142.11 | -6.41% | 3 | Dec 16, 2025 | |
| MIST Milestone Pharmaceuticals | Upgrades: Buy | $8 | $1.78 | +349.44% | 1 | Dec 15, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $251 → $353 | $309.91 | +13.90% | 1 | Dec 8, 2025 | |
| VERA Vera Therapeutics | Maintains: Buy | $60 → $73 | $40.25 | +81.37% | 2 | Dec 5, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $390 → $554 | $432.78 | +28.01% | 2 | Aug 26, 2025 | |
| SPRO Spero Therapeutics | Downgrades: Hold | n/a | $2.45 | - | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $5.46 | - | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $282 → $371 | $322.38 | +15.08% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.53 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $175 | $17.66 | +890.94% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $62.79 | - | 2 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.00 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $15.76 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.14 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $45.29 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.39 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.38 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $529.97 | - | 2 | Jan 12, 2018 |
ACADIA Pharmaceuticals
Feb 26, 2026
Maintains: Buy
Price Target: $35 → $37
Current: $22.54
Upside: +64.15%
Krystal Biotech
Jan 9, 2026
Maintains: Buy
Price Target: $202 → $306
Current: $261.08
Upside: +17.21%
vTv Therapeutics
Jan 5, 2026
Initiates: Buy
Price Target: $67
Current: $35.02
Upside: +91.32%
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $269 → $241
Current: $143.85
Upside: +67.54%
Palvella Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $97 → $133
Current: $142.11
Upside: -6.41%
Milestone Pharmaceuticals
Dec 15, 2025
Upgrades: Buy
Price Target: $8
Current: $1.78
Upside: +349.44%
Praxis Precision Medicines
Dec 8, 2025
Maintains: Buy
Price Target: $251 → $353
Current: $309.91
Upside: +13.90%
Vera Therapeutics
Dec 5, 2025
Maintains: Buy
Price Target: $60 → $73
Current: $40.25
Upside: +81.37%
Madrigal Pharmaceuticals
Aug 26, 2025
Maintains: Buy
Price Target: $390 → $554
Current: $432.78
Upside: +28.01%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.45
Upside: -
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $5.46
Upside: -
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $322.38
Upside: +15.08%
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $5.53
Upside: -
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $17.66
Upside: +890.94%
Nov 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $62.79
Upside: -
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.00
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $15.76
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.14
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $45.29
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.39
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $0.38
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $529.97
Upside: -